Engineering improved technology for nanoparticle-based adjuvant manufacture

基于纳米颗粒的佐剂制造的工程改进技术

• 批准号: LP140100424
• 负责人: Prof Chun-Xia Zhao
• 金额: $ 21.15万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-21 至 2019-04-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP140100424
• 关键词: Engineering; improved; technology; nanoparticle; based

Over the next decade nanotechnology will redefine vaccines for animal and human health. Nanoparticle adjuvants will boost engineered vaccines that use minimal antigens such as recombinant proteins and synthetic peptides. This project aims to develop a platform technology for making and controlling the properties of inulin nanoparticles by optimising the engineering and manufacturing aspects of inulin nanoparticles to fundamentally understand the relationship between physical-chemical properties and efficacy. Completion of this project aims to produce potent nanoparticle-based adjuvants underpinned by novel manufacturing technology, to ultimately facilitate the development of more effective and protective vaccines for animals and humans.

在未来十年，纳米技术将重新定义动物和人类健康的疫苗。纳米颗粒佐剂将促进使用最小抗原（如重组蛋白和合成肽）的工程疫苗。该项目旨在通过优化菊粉纳米颗粒的工程和制造方面来开发用于制造和控制菊粉纳米颗粒特性的平台技术，以从根本上了解物理化学特性和功效之间的关系。该项目的完成旨在生产以新型制造技术为基础的基于纳米颗粒的有效佐剂，最终促进为动物和人类开发更有效和保护性的疫苗。